Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1451-1458

  Liu, Zhaoxu ^a,b   Marquez, Marcela ^a   Nilsson, Sten ^a   Holmberg, Anders R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHANDONG UNIVERSITY   (China)

Author keywords

2 DE; Mass spectrometry; Prostate cancer; Protein expression; Somatostatin

Indexed keywords

ACETYL COENZYME A ACETYLTRANSFERASE; ALPHA ENOLASE; COFILIN; CREATINE KINASE; CYTOKERATIN 2; CYTOSOL AMINOPEPTIDASE; DIHYDROLIPOAMIDE DEHYDROGENASE; FIBROBLAST GROWTH FACTOR 5; FLAVOPROTEIN; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; GLYOXALASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN BETA 1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C; LAMIN B; LENS EPITHELIUM DERIVED GROWTH FACTOR; MALATE DEHYDROGENASE; MITOCHONDRIAL PROTEIN; PEROXIREDOXIN 2; POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE; PROTEIN DISULFIDE ISOMERASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; SEPTIN; SEPTIN 2; SOMATOSTATIN DERIVATIVE; THIOREDOXIN REDUCTASE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; QUANTITATIVE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOMATOSTATIN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 70449389068     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000587     Document Type: Article

References (29)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics 1996. CA Cancer J Clin 46: 5-27, 1996.
2. Denis L and Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72 (Suppl. 12): S3888-S3895, 1993.
3. Liu Z, Márquez M, Nilsson S, Holmberg AR and Alaiya AA: Proteomic analysis of a human prostate cancer cell line after incubation with a novel somatostatin14 derivative. Cancer Genomics Proteomics 2: 347-352, 2005.
4. Liu Z, Bengtsson S, Krogh M, et al: Somatostatin effects on the proteome of the LNCaP cell-line. Int J Oncol 30: 1173-1179, 2007.
5. Liu Z, Márquez M, Nilsson S and Holmberg AR: Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep 20: 151-154, 2008.
6. Brevini TA, Bianchi R and Motta M: Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J Clin Endocrinol Metab 77: 626-631, 1993.
7. Franzén B, Linder S, Okuzawa K, Kato H and Auer G: Non-enzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14: 1045-1053, 1993.
8. Rabilloud T, Vuillard L, Gilly C and Lawrence JJ: Silver-staining of proteins in polyacrylamide gels: a general overview. Cell Mol Biol 40: 57-75, 1994.
9. Garrels JI: The QUEST system for quantitative analysis of two-dimensional gels. J Biol Chem 264: 5269-5282, 1989.
10. Damber JE and Aus G: Prostate cancer. Lancet 371: 1710-1721, 2008.
11. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
12. Machiels JP, Mazzeo F, Clausse M, et al: Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 26: 5261-5268, 2008.
13. Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
14. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A and Lambou T: A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 86: 5729-5736, 2001.
15. Koutsilieris M, Mitsiades CS, Bogdanos J, et al: Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 10: 4398-4405, 2004.
16. Florio T: Somatostatin/somatostatin receptor signalling, phosphotyrosine phosphatases. Mol Cell Endocrinol 286: 40-48, 2008.
17. Florio T, Thellung S, Arena S, et al: Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol 94: 239-250, 2000.
18. Kosari F, Munz JM, Savci-Heijink CD, et al: Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 14: 1734-1743, 2008.
19. Wu M, Bai X, Xu G, et al: Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression. Proteomics 7: 1973-1983, 2007.
20. Yang Z, Chang YJ, Miyamoto H, et al: Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54. Endocrinology 148: 1340-1349, 2007.
21. Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M and Garrido C: Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 12: 743-761, 2008.
22. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: antiapoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601, 2006.
23. Arcuri F, Papa S, Carducci A, et al: Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate 60: 130-140, 2004.
24. Susini L, Besse S, Duflaut D, et al: TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 15: 1211-1220, 2008.
25. Zeng L, Imamoto A and Rosner MR: Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets 12: 1275-1287, 2008.
26. Keller ET, Fu Z, Yeung K and Brennan M: Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Lett 207: 131-137, 2004.
27. Fu Z, Smith PC, Zhang L, et al: Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95: 878-879, 2003.
28. Chatterjee D, Bai Y, Wang Z, et al: RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279: 17515-17523, 2004.
29. Fougner SL, Bollerslev J, Latif F, et al: Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab 93: 1211-1216, 2008.